Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Main Criteria for Inclusion:~* Men or women ≥18 years of age at the time of screening.~* Subjects with chronic plaque type psoriasis diagnosed at least 6 months before randomisation.~* Subjects with moderate to severe plaque psoriasis in whom topical therapy is not adequate and who are candidates for systemic therapy, defined at randomisation by PASI 10, affected BSA \>10%, and DLQI \>10.~* Subject has no known history of active tuberculosis.~* Subject has a negative test for tuberculosis taken at screening (negative Quantiferon test).~* Subject and/or subject's designee is/are capable of administering subcutaneous injections.~Main Criteria for Exclusion:~* Previous or current systemic treatment of plaque psoriasis or known contraindication for systemic therapy.~* Previous or current PUVA (psoralens and ultraviolet A) therapy.~* Washouts and non-permitted drugs:~  1. Have received phototherapy (UVA light therapy without psoralens, UVB light therapy, excimer laser, tanning beds etc. within 4 weeks of baseline, or~ 2. Have had topical psoriasis treatment within 2 weeks of baseline (exceptions: bland emollients without urea or beta or alpha hydroxy acids)~ 3. Have received any biologic immune modulating treatments used for indication other than psoriasis within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer~ 4. Have received any other systemic immune modulating treatment (including but not limited to oral retinoids, methotrexate, calcineurin inhibitors, oral or parenteral corticosteroids etc. used for indications other than psoriasis) within 4 weeks of baseline or within a period of 5 half-lives of the IMP, whichever is longer.~* Subjects with any of the following laboratory abnormalities at screening:~  1. Leukocyte cell count below 3×10\^9/L or lymphocyte count below 0.7×10\^9/L~ 2. Aspartate aminotransferase (AST) or alanine transferase (ALT) \> 2× ULN (upper level of normal limit)~ 3. Absolute neutrophil count \< 2×10\^9/L~ 4. Serum creatinine \> ULN.~* History of depressive disorder within the last 2 years including current antidepressive treatment.~* Subjects with a history of suicidal behaviour (suicide attempt).~* Any suicidal ideation of severity 4 or 5 based on the eC-SSRS questionnaire at screening.~* A PHQ-8 score of ≥10 corresponding to moderate to severe depression at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brodalumab (Type: EXPERIMENTAL): Kyntheum® (brodalumab)~pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.~First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
- Fumaric acid esters (Type: ACTIVE_COMPARATOR): Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)~Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)~Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label.

Based on this trial design, predict the completion outcome and termination type (if applicable).